Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab vs Mepolizumab in Relapsing or Refractory EGPA
NCT05263934Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2022
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of depemokimab in eosinophilic granulomatosis with polyangiitis (EGPA) (2 arms), sponsored by GSK. Primary endpoint: Number of participants with remission. Started Jul 2022; status: active, not recruiting.
02
Drugs
depemokimab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT05263934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263934.